Home・Lista de Ações・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Fechado

SetorSaúde

19.11 1.16

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.8

Máximo

19.34

Indicadores-chave
By Trading Economics
Rendimento	-24M -54M
Vendas	-2.5M 305M
EPS	-0.15
Margem de lucro	-17.851
Funcionários	3,100
EBITDA	-24M -32M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+175.38% upside

Dividendos
By Acuity
Próximos Ganhos	11 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1B 3.7B
Abertura anterior	17.95
Fecho anterior	19.11

Sentimento de Notícias

By Acuity

100%

320 / 340 Ranking em Healthcare

Legend Biotech Corp ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 de jul. de 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 de jul. de 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 de jul. de 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 de jul. de 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 de jul. de 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 de jul. de 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 de jul. de 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 de jul. de 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 de jul. de 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Comparação entre Pares

Variação de preço

Legend Biotech Corp ADR Previsão

Preço-alvo

By TipRanks

175.38% parte superior

Previsão para 12 meses

Média 52.35 USD 175.38%

Máximo 80 USD

Mínimo 28 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Legend Biotech Corp ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Legend Biotech Corp ADR - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.